Comparison
Plasma biomarkers vs brain-derived EV biomarkers: which does your CNS trial need?
Whole-plasma immunoassays measure the total level of a protein in blood. Brain-derived extracellular vesicle (EV) assays first isolate vesicles released by brain cells, then measure inside them. Plasma assays work well for markers made mostly in the brain, such as NfL, GFAP and p-Tau217. EV assays are needed when the target is also made elsewhere in the body, such as TDP-43 or α-synuclein, or when a trial must show a drug changed brain biology. Most CNS programs benefit from both.
Side-by-side
| Whole-plasma immunoassay | Brain-derived EV assay | |
|---|---|---|
| What is measured | Total amount of a protein in plasma, from every tissue that makes it | Proteins and RNA inside vesicles released by brain cells, such as neurons and oligodendrocytes |
| Where the signal comes from | Mixed. Works best for markers made mostly in the CNS | Tied to the brain by isolating brain-derived vesicles before measuring |
| Best suited to | Neuronal injury (NfL), astroglial activation (GFAP), Alzheimer’s pathology (p-Tau217, Aβ42/40) | Targets also made outside the brain (TDP-43, α-synuclein), signalling pathways (Akt–mTOR), autophagy, synaptic proteins, mRNA |
| Target engagement | Limited for intracellular targets, because peripheral levels mask brain changes | Measures the target and its pathway in brain-derived vesicles at every visit |
| Mechanism or disease process | Usually reports damage or pathology, not which protein drives it | Can report protein-specific biology, such as neuronal TDP-43 or α-synuclein |
| Sample | Small volume of plasma or serum | 500 µL EDTA plasma or serum |
| Workflow | Direct measurement, highly automated | Extra isolation step (automated 96-well), then measurement |
| Main limitation | Peripheral expression can drown out the brain signal for many targets | Each assay must be qualified in the vesicle matrix |
When to use which
- Plasma first for screening, Alzheimer’s pathology and neuronal injury: p-Tau217, Aβ42/40, GFAP and NfL. See the Cognilera® Tier 1 panel.
- Brain-derived EVs for target engagement and pharmacodynamics, for TDP-43 and α-synuclein biology, and for pathway or mRNA readouts. See CNS pharmacodynamic biomarkers.
- Both together when a trial needs to know who has the disease and whether the drug is changing it, from the same blood draw.
How NeuroDex runs both
NeuroDex isolates brain-derived vesicles with its ExoSORT™ platform, using proprietary antibodies against neuronal and oligodendroglial surface proteins. Published validation shows more than 50-fold neuronal signal compared with plasma. Neuron-derived TDP-43 measured this way was a registered primary outcome in the Phase 2b PARADIGM ALS trial. The plasma layer, p-Tau217, Aβ42/40, GFAP and NfL, is available through Cognilera®. See the full list of validated analytes and NfL vs neuron-derived exosome biomarkers.
Before you commit samples
Request a sample-feasibility review
Tell us your target, sample type and volume, number of visits and study size. We will tell you which panels fit, what your banked samples can support and the expected turnaround, typically 2–3 weeks from sample receipt.
FAQ
Plasma vs brain-derived EV biomarkers: common questions
What is the difference between plasma biomarkers and brain-derived EV biomarkers?
Plasma biomarkers measure the total level of a protein in blood, from all tissues. Brain-derived extracellular vesicle (EV) biomarkers are measured inside vesicles released by brain cells, which ties the signal to the brain.
When are plasma biomarkers enough?
When the marker is made mostly in the central nervous system and the question is about injury or Alzheimer’s pathology, for example NfL, GFAP, p-Tau217 and Aβ42/40.
When do you need brain-derived EV biomarkers?
When the target is also made outside the brain, such as TDP-43, α-synuclein or Akt, or when a trial needs to show that a drug changed brain biology without a lumbar puncture.
Can a trial use both?
Yes. Many programs pair plasma markers of injury or pathology with brain-derived EV markers of mechanism and target engagement from the same blood draw.

